<DOC>
	<DOCNO>NCT02868996</DOCNO>
	<brief_summary>This Phase 1B study ass safety , tolerability pharmacokinetics DM199 healthy volunteer . The study consist two part : Part A focus intravenous dose Part B directly compare intravenous dose subcutaneous dosing .</brief_summary>
	<brief_title>An Open Label , Phase 1b , Ascending Dose Study DM199</brief_title>
	<detailed_description />
	<mesh_term>Kallikreins</mesh_term>
	<criteria>1 . Male female 18 50 year age ( inclusive ) ; 2 . Healthy clinically significant medical problem ; 3 . BMI 18 30 kg/m2 weight 50 100 kg ( inclusive ) ; 4 . No history alcohol drug abuse ( Paracetamol , Barbiturates , Benzodiazepines , Cocaine , Methadone , Amphetamines , Methamphetamines , Opiates , Phencyclidine , Tetrahydrocannabinol ( cannabis ) , Tricyclic Antidepressants ) . Subjects enrol pass urine drug screen ( positive test paracetamol allow ) ; 5 . Nonsmokers light smoker ( Less 5 cigarette per day ) history plan study ; 6 . No history significant allergic diathesis urticaria , angioedema anaphylaxis ; 7 . Receiving chronic medication affect blood pressure control , bradykinin angiotensin system include angiotensinconvertingenzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) ; 8 . Willing able sign write , informed consent . 1 . Any significant past current cardiac , pulmonary , hepatic , renal medical condition opinion investigator would make participation subject study medically unsafe compromise accuracy assessment safety , pharmacokinetic pharmacodynamic data study ; 2 . Subjects abnormal safety lab outside local lab range exclude PI 's discretion base his/her assessment clinical significance ( repeat screen PI 's discretion ) ; 3 . Subjects past medical history malignancy except basal cell squamous cell carcinoma skin curative surgical treatment least 6 month elapse since procedure ; 4 . A value outside specify range 90 mm Hg 140 mm Hg systolic blood pressure 50 mm Hg 90 mm Hg diastolic blood pressure ( inclusive ) screening ( repeat screen per PI 's discretion ) ; 5 . Subjects use angiotensinconvertingenzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) control blood pressure ; 6 . History clinically significant acute bacterial , viral , fungal systemic infection last 4 week prior screen ; 7 . Clinical laboratory evidence active infection time screen ; 8 . Known alpha 1antitrypsin deficiency ( Î±1antitrypsin deficiency ) ; 9 . Serological evidence human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( AntiHCV ) screening ; 10 . Vaccination within 3 month screen study require vaccination study within 3 month completion study ; 11 . Females pregnant nursing ; 12 . Females childbearing potential ( i.e. , woman surgically sterile e.g. , hysterectomy , bilateral oophorectomy &gt; 1year postmenopause status confirm folliclestimulating hormone ( FSH ) level define establish lab range ) men , participate heterosexual sexual activity could lead pregnancy unable unwilling practice medically effective contraception study . They agree use two reliable method contraception ( e.g. , doublebarrier condom plus diaphragm , condom diaphragm plus stable dose hormonal contraception ) throughout study period 3 month receive study drug . Women childbearing potential require compulsory pregnancy test . A negative pregnancy test ( serum urine ) document screen Day 1 respectively ; 13 . Participation drug study within 8 week 5 halflives study drug , whichever longer ; 14 . Unable unwilling comply protocol requirement study visit procedure ; 15 . Subjects good venous access infusion study drug blood sampling ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>